Opeyemi Olabisi
Assistant Professor of Medicine
Current Appointments & Affiliations
- Assistant Professor of Medicine, Medicine, Nephrology, Medicine 2019
- Member of Duke Molecular Physiology Institute, Duke Molecular Physiology Institute, Duke Molecular Physiology Institute 2019
Contact Information
- Background
-
Education, Training, & Certifications
- Fellowship, Nephrology, Massachusetts General Hospital 2012 - 2015
- Residency, Internal Medicine, Massachusetts General Hospital 2010 - 2012
- M.D., Yeshiva University, Albert Einstein College of Medicine 2009
- Ph.D., Yeshiva University, Albert Einstein College of Medicine 2009
- Recognition
-
In the News
-
NOV 10, 2021 Duke Clinical and Translational Institute -
OCT 1, 2019 -
JUL 15, 2019
-
- Research
-
Selected Grants
- Duke Preparing Research Scholars in Biomedical Sciences- Post-Baccalaureate Research Education Program awarded by National Institutes of Health 2022 - 2027
- Mechanisms of HIV persistence in the kidney (R01) awarded by National Institutes of Health 2022 - 2027
- REGULATORS OF CALCINEURIN PATHWAYS AS DIAGNOSTIC AND THERAPEUTIC TARGETS FOR NEPHROTIC SYNDROME awarded by National Institutes of Health 2023 - 2026
- JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease awarded by National Institutes of Health 2021 - 2026
- A-018101 Lilly USA awarded by Lilly USA, LLC 2022 - 2026
- A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin awarded by Vertex Pharmaceuticals Inc. 2020 - 2025
- A Human Stem Cell-Derived Podocyte Model for APOL1 Nephropathy awarded by National Institutes of Health 2019 - 2024
- Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE III) ("Study") awarded by Regents of the University of Michigan 2019 - 2023
- Duke Training Grant in Nephrology awarded by National Institutes of Health 1995 - 2023
- Etiology of Persistent Microalbuminuria in Nigeria awarded by Vanderbilt University Medical Center 2021 - 2023
- A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX¿147 in Adults With APOL1-dependent Focal Segmental Glomerulosclerosis awarded by Vertex Pharmaceuticals Inc. 2020 - 2022
- A Natural History Study of Patients With Biopsy-proven Focal Segmental Glomerulosclerosis and Nephrotic Range Proteinuria Who Are of Recent African Ancestry or Have 2 APOL1 Risk Alleles awarded by Vertex Pharmaceuticals Inc. 2020 - 2022
- Icagen SRA awarded by Icagen, Inc 2021 - 2022
- Unmasking the Molecular Mechanism of ApoL1 Nephropathy awarded by Robert Wood Johnson Foundation 2020
-
External Relationships
- Chinook Therapeutics
- Icagen, Inc (Pfizer)
- Maze Therapeutics
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Mohottige, Dinushika, Opeyemi Olabisi, and L Ebony Boulware. “Use of Race in Kidney Function Estimation: Lessons Learned and the Path Toward Health Justice.” Annu Rev Med 74 (January 27, 2023): 385–400. https://doi.org/10.1146/annurev-med-042921-124419.Full Text Link to Item
-
Hingorani, S., K. L. Gibson, Y. Xie, Y. Wang, S. Eddy, J. Hartman, M. Sampson, et al. “The association of low birthweight and prematurity on outcomes in children and adults with nephrotic syndrome—a NEPTUNE cohort study.” Pediatric Nephrology, January 1, 2023. https://doi.org/10.1007/s00467-023-05876-3.Full Text
-
Olabisi, Opeyemi A., Susanne B. Nicholas, and Keith C. Norris. “Race, Ancestry, and Genetic Risk for Kidney Failure.” Am J Kidney Dis 80, no. 6 (December 2022): 801–4. https://doi.org/10.1053/j.ajkd.2022.08.008.Full Text Link to Item
-
Wester, C William, Bryan E. Shepherd, Usman J. Wudil, Baba Maiyaki Musa, Donna J. Ingles, Heather L. Prigmore, Faisal S. Dankishiya, et al. “Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study design.” Bmc Infect Dis 22, no. 1 (July 4, 2022): 591. https://doi.org/10.1186/s12879-022-07531-y.Full Text Link to Item
-
Nystrom, Sarah E., Guojie Li, Somenath Datta, Karen L. Soldano, Daniel Silas, Astrid Weins, Gentzon Hall, David B. Thomas, and Opeyemi A. Olabisi. “JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.” Jci Insight 7, no. 11 (June 8, 2022). https://doi.org/10.1172/jci.insight.157432.Full Text Link to Item
-
National Kidney Foundation Research Roundtable Work Group on behalf of the National Kidney Foundation, Hongbing. “Research Priorities for Kidney-Related Research-An Agenda to Advance Kidney Care: A Position Statement From the National Kidney Foundation.” Am J Kidney Dis 79, no. 2 (February 2022): 141–52. https://doi.org/10.1053/j.ajkd.2021.08.018.Full Text Link to Item
-
DeOliveira, Margaret, Colby Feeney, Caroline Leahy, Sarah Nystrom, David N. Howell, Samira S. Farouk, Ming Wu, Opeyemi A. Olabisi, and Matthew A. Sparks. “Collapsing Glomerulopathy in Identical Twins With Lupus and High-Risk Apolipoprotein L1 (APOL1) Genotype.” Kidney Int Rep 6, no. 9 (September 2021): 2501–4. https://doi.org/10.1016/j.ekir.2021.06.005.Full Text Link to Item
-
Freedman, Barry I., Wylie Burke, Jasmin Divers, Lucy Eberhard, Crystal A. Gadegbeku, Rasheed Gbadegesin, Michael E. Hall, et al. “Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review.” J Am Soc Nephrol 32, no. 7 (July 2021): 1765–78. https://doi.org/10.1681/ASN.2020101399.Full Text Link to Item
-
Olabisi, Opeyemi A., and Barry I. Freedman. “APOL1-associated kidney disease in northern Nigerians with treated HIV infection.” Kidney Int 100, no. 1 (July 2021): 19–21. https://doi.org/10.1016/j.kint.2021.04.023.Full Text Link to Item
-
Datta, Somenath, Rama Kataria, Jia-Yue Zhang, Savannah Moore, Kaitlyn Petitpas, Adam Mohamed, Nathan Zahler, Martin R. Pollak, and Opeyemi A. Olabisi. “Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function.” J Am Soc Nephrol 31, no. 9 (September 2020): 2083–96. https://doi.org/10.1681/ASN.2020010079.Full Text Open Access Copy Link to Item
-
Norris, Keith C., Opeyemi Olabisi, M Edwina Barnett, Yuan-Xiang Meng, David Martins, Chamberlain Obialo, Jae Eun Lee, and Susanne B. Nicholas. “The Role of Vitamin D and Oxidative Stress in Chronic Kidney Disease.” Int J Environ Res Public Health 15, no. 12 (November 30, 2018). https://doi.org/10.3390/ijerph15122701.Full Text Link to Item
-
Olabisi, Opeyemi A., and John F. Heneghan. “APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?” Semin Nephrol 37, no. 6 (November 2017): 546–51. https://doi.org/10.1016/j.semnephrol.2017.07.008.Full Text Link to Item
-
Olabisi, Opeyemi A., Jia-Yue Zhang, Lynn VerPlank, Nathan Zahler, Salvatore DiBartolo, John F. Heneghan, Johannes S. Schlöndorff, et al. “APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.” Proc Natl Acad Sci U S A 113, no. 4 (January 26, 2016): 830–37. https://doi.org/10.1073/pnas.1522913113.Full Text Link to Item
-
Suk, Hee Yun, Chen Zhou, Teddy T. C. Yang, Hong Zhu, Raymond Y. L. Yu, Opeyemi Olabisi, XiaoYong Yang, et al. “Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases.” J Biol Chem 288, no. 5 (February 1, 2013): 3477–88. https://doi.org/10.1074/jbc.M112.419150.Full Text Link to Item
-
Olabisi, Opeyemi A., and Chi-Wing Chow. “Assay for protein modification by poly-ADP-ribose in vitro.” Methods Mol Biol 780 (2011): 47–55. https://doi.org/10.1007/978-1-61779-270-0_3.Full Text Link to Item
-
Zhu, Hong, Hee Yun Suk, Raymond Y. L. Yu, Deborah Brancho, Opeyemi Olabisi, Teddy T. C. Yang, XiaoYong Yang, et al. “Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D.” Mol Cell Biol 30, no. 18 (September 2010): 4379–90. https://doi.org/10.1128/MCB.01193-09.Full Text Link to Item
-
Olabisi, Opeyemi A., Noemi Soto-Nieves, Edward Nieves, Teddy T. C. Yang, Xiaoyong Yang, Raymond Y. L. Yu, Hee Yun Suk, Fernando Macian, and Chi-Wing Chow. “Regulation of transcription factor NFAT by ADP-ribosylation.” Mol Cell Biol 28, no. 9 (May 2008): 2860–71. https://doi.org/10.1128/MCB.01746-07.Full Text Link to Item
-
Yang, Teddy T. C., Hee Yun Suk, Xiaoyong Yang, Opeyemi Olabisi, Raymond Y. L. Yu, Jorge Durand, Linda A. Jelicks, et al. “Role of transcription factor NFAT in glucose and insulin homeostasis.” Mol Cell Biol 26, no. 20 (October 2006): 7372–87. https://doi.org/10.1128/MCB.00580-06.Full Text Link to Item
-
Broderick, Patricia A., Opeyemi A. Olabisi, David N. Rahni, and Yueping Zhou. “Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.” Prog Neuropsychopharmacol Biol Psychiatry 28, no. 3 (May 2004): 547–57. https://doi.org/10.1016/j.pnpbp.2004.01.007.Full Text Link to Item
-
Olabisi, Opeyemi, Khaldoun Al-Romaih, Joel Henderson, Ritu Tomar, Iain Drummond, Calum MacRae, and Martin Pollak. “From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?” Clin Nephrol 86 (2016), no. 13 (n.d.): 114–18. https://doi.org/10.5414/CNP86S116.Full Text Link to Item
-
-
Book Sections
-
Olabisi, O., and J. V. Bonventre. “Acute kidney injury in cancer patients.” In Onconephrology: Cancer, Chemotherapy and the Kidney, 1–24, 2015. https://doi.org/10.1007/978-1-4939-2659-6_1.Full Text
-
-
Conference Papers
-
Wu, Dongling, Opeyemi Olabisi, Zachary Kozel, Oksana Yaskiv, Yihe Yang, and Vanesa Bijol. “ApoL1 Genotype in African American Patients with Kidney Neoplasm.” In Laboratory Investigation, 102:695–97, 2022.Link to Item
-
Wu, Dongling, Opeyemi Olabisi, Zachary Kozel, Oksana Yaskiv, Yihe Yang, and Vanesa Bijol. “ApoL1 Genotype in African American Patients with Kidney Neoplasm.” In Modern Pathology, 35:695–97, 2022.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
